After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

FGL Holdings views itself as a distinctive entity with fair valuation, citing a multiple of 7.7 times its estimated 2025 earnings, compared to the coverage average of 8.2 times. The company also ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

On Wednesday, Barclays began coverage on FGL Holdings (NYSE:FG_old) (NYSE:FG) with an Equalweight rating and set a price target of $45.00. The firm's stance on the insurance holding company is ...

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...

ITeos’ drug has drawn attention in large part due to the protein that it targets. Called TIGIT, the protein is thought to stifle the immune response to cancer, suggesting that blocking it could ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...